Biologic CDMO Tanvex launched Tanvex CDMO to offer comprehensive biologic contract development and manufacturing services, indicating a potential collaboration avenue for biosimilars, novel biologics, and scale-up capabilities.

Biosimilar Growth Recent launch of Nypozi (filgrastim) in the US via a marketing partner suggests active biosimilar commercialization and distribution channels; target partners may include large biopharma firms seeking biosimilar access.

Strategic Partnerships Past collaboration with Alcami and ongoing CDMO expansion imply openness to strategic alliances; identify partners seeking manufacturing capacity, development support, or shared regulatory pathways.

US Presence Based in San Diego with 51-200 employees and revenue in the 50–100 million range, Tanvex is a mid-sized US-based biosimilar and biologics player with potential capacity for US-facing development programs and localized supply.

Leadership & IP risk Past patent litigation activity around TX05 highlights IP considerations; outline risk assessment and offer collaboration opportunities that emphasize compliant development, robust IP diligence, and risk-managed pathways.